Pharmaceutical Executive
Promising drugs failed to deliver at this year's American College of Cardiology meeting.
Pharmaceutical Executive-04-04-2007
Pharmaceutical Executive
High-profile, quick-growing IBS drug shelved because of cardio risks.
Pharmaceutical Executive
New technology could revolutionize meningitis strategy in the developing world.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
